ROBIN NORMAN: Open Payments
NPI 1760421721 · WASHINGTON COURT HOUSE, OH. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,189 in 69 payments from 12 companies in 2025. Trend: 2023 $1,375 · 2024 $1,248 · 2025 $1,189
Food & beverage: $1,189
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 18 | $329 |
| Teva Pharmaceuticals USA, Inc. | 14 | $222 |
| Neurocrine BioSciences, Inc. | 11 | $167 |
| Lundbeck LLC | 6 | $97 |
| Supernus Pharmaceuticals, Inc. | 5 | $88 |
| ABBVIE INC. | 3 | $66 |
| E.R. Squibb & Sons, L.L.C. | 3 | $50 |
| Axsome Therapeutics, Inc. | 2 | $49 |
| Janssen Pharmaceuticals, Inc | 2 | $36 |
| Alkermes, Inc. | 2 | $33 |
Products named: REXULTI, ABILIFY ASIMTUFII, INGREZZA, AUSTEDO XR, UZEDY, Qelbree, ABILIFY MAINTENA, VRAYLAR.
Industry payments across OH — which companies pay providers there.
